Potential of Pretreatment Neural Activity in the Visual Cortex During Emotional Processing to Predict Treatment Response to Scopolamine in Major Depressive Disorder

Furey, Maura L.; Drevets, Wayne C.; Hoffman, Elana M.; Frankel, Erica; Speer, Andrew B.; Zarate, Carlos A.

doi:10.1001/2013.jamapsychiatry.60

Cited by 91 publications

(81 citation statements)

References 55 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as cited above, our group and others have demonstrated differential levels of amino acid neurotransmitters with response to successful antidepressant therapies in the occipital cortex. Additionally, there are several recent studies demonstrating abnormal function of the visual cortex in depression that changes [51, 52] and possibly predicts treatment outcome [53]. A third major limitation of our study is the absence of a non-intervention (“placebo”) group in both the CBT and pharmacotherapy phases to control for non-specific clinical and neuroimaging effects.…”

Section: Discussionmentioning

confidence: 99%

Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder

Abdallah

Niciu²,

Fenton³

et al. 2014

Psychother Psychosom

View full text Add to dashboard Cite

Background: Previous studies have demonstrated that antidepressant medication and electroconvulsive therapy increase occipital cortical γ-aminobutyric acid (GABA) in major depressive disorder (MDD), but a small pilot study failed to show a similar effect of cognitive-behavioral therapy (CBT) on occipital GABA. In light of these findings we sought to determine if baseline GABA levels predict treatment response and to broaden the analysis to other metabolites and neurotransmitters in this larger study. Methods: A total of 40 MDD outpatients received baseline proton magnetic resonance spectroscopy (¹H-MRS), and 30 subjects completed both pre- and post-CBT ¹H-MRS; 9 CBT nonresponders completed an open-label medication phase followed by an additional/3rd ¹H-MRS. The magnitude of treatment response was correlated with occipital amino acid neurotransmitter levels. Results: Baseline GABA did not predict treatment outcome. Furthermore, there was no significant effect of CBT on GABA levels. However, we found a significant group × time interaction (F_{1, 28} = 6.30, p = 0.02), demonstrating reduced glutamate in CBT responders, with no significant glutamate change in CBT nonresponders. Conclusions: These findings corroborate the lack of effect of successful CBT on occipital cortical GABA levels in a larger sample. A reduction in glutamate levels following treatment, on the other hand, correlated with successful CBT and antidepressant medication response. Based on this finding and other reports, decreased occipital glutamate may be an antidepressant response biomarker. Healthy control comparator and nonintervention groups may shed light on the sensitivity and specificity of these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder

Abdallah

Niciu²,

Fenton³

et al. 2014

Psychother Psychosom

View full text Add to dashboard Cite

show abstract

“…Ketamine and scopolamine have been shown to have antidepressant effects which emerge in hours to days rather than weeks, making them intriguing candidates for exploring prediction of effects [32]. Furey et al [33] examined the prediction of the rapid antidepressant effect of scopolamine using fMRI during a face identity and face emotion working memory task in 15 depressed patients. Baseline BOLD response in the bilateral middle occipital cortex, specifically during emotion working memory, correlated with treatment response magnitude (percentage change in MADRS).…”

Section: Novel Candidate Antidepressant Treatmentsmentioning

confidence: 99%

Neural Predictors of Treatment Response in Depression

Harmer

2014

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Depression is a leading cause of disability and treatment response is highly variable between patients. The current review focuses on recent findings from studies exploring neural predictors of treatment response to conventional antidepressant drugs, psychological treatment, and novel candidate interventions. Structural markers of response have revealed that decreased volume of key substrates such as the hippocampus and orbitofrontal cortex are predictive of poor response to antidepressant drug treatment, and diffusion tensor imaging offers potentially relevant information for future studies. Pretreatment measures of rostral anterior cingulate activity (from functional magnetic resonance imaging-and electroencephalogram-based approaches) have also been highlighted as a biomarker for antidepressant drug response. The relative utility of measurements taken at baseline versus early change for refining treatment in individual patients is considered. The response to novel treatments such as scopolamine, ketamine, and deep brain stimulation also offer promise for understanding targets of treatment and predictors for tailoring treatment. There is considerable overlap between neural biomarkers for different treatments although positron emission tomography metabolism in the anterior insula may offer a differential predictor of response to pharmacotherapy versus psychotherapy in depression. These insights provide important information about the potential targets and mechanisms underlying the prediction of treatment effects in depression. Future work needs to explore these different predictors between treatment arms in prospectively defined studies to evaluate whether these markers may have utility in the clinic.

show abstract

“…Therefore, an urgent need exists to identify clinically applicable predictors of treatment response. Prediction tools studied previously include clinical parameters (Fava et al 2008), functional neuroimaging (Furey et al 2013;Samson et al 2011), quantitative electroencephalography ), (pharmaco)genetics (Benedetti et al 2012;Binder et al 2010;Brouwer et al 2006;Hunter et al 2013;McMahon et al 2006;Tansey et al 2012), and gene expression profiling ).…”

Section: Introductionmentioning

confidence: 99%

Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy

et al. 2015

View full text Add to dashboard Cite

show abstract

Potential of Pretreatment Neural Activity in the Visual Cortex During Emotional Processing to Predict Treatment Response to Scopolamine in Major Depressive Disorder

Cited by 91 publications

References 55 publications

Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder

Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder

Neural Predictors of Treatment Response in Depression

Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy

Contact Info

Product

Resources

About